Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1694767 | 0.82 | ALDH1A1 (0.50) | ALDH1A1KDM4EBACE1KEAP1PTPN1 | |
| SCHEMBL12395484 | 0.80 | PIM1 (0.47) | ALDH1A1KDM4EMEN1LMNAKMT2A | |
| SCHEMBL29957006 | 0.78 | ERN1 (0.46) | ALDH1A1KDM4EPTPN1MEN1LMNA | |
| SCHEMBL4363014 | 0.78 | ERN1 (0.46) | ALDH1A1KDM4EPTPN1MEN1LMNA | |
| SCHEMBL17873440 | 0.77 | ALDH1A1 (0.44) | ALDH1A1KDM4EBACE1KEAP1AXL | |
| SCHEMBL31395718 | 0.77 | ALDH1A1 (0.44) | ALDH1A1KDM4EBACE1KEAP1AXL | |
| SCHEMBL1350147 | 0.77 | ALDH1A1 (0.48) | ALDH1A1KDM4EPTPN1ERN1NFE2L2 | |
| SCHEMBL2334691 | 0.76 | CASP1 (0.42) | ALDH1A1KDM4EMEN1LMNAKMT2A | |
| SCHEMBL18181691 | 0.76 | KDM4E (0.44) | ALDH1A1KDM4EPTPN1MEN1LMNA | |
| SCHEMBL31556816 | 0.76 | TDP1 (0.48) | ALDH1A1KDM4EMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118239956-A | Preparation of 11-fluorocamptothecin derivative and application thereof in anti-tumor aspect | 兰州大学 | 2024-06-25 | — | — | CN | claimed |
| CN-107188851-B | Method for synthesizing astemizole key intermediate and derivative thereof | 湖南大学 | 2020-04-07 | — | — | CN | claimed |
| CN-107188851-A | A kind of method for synthesizing astemizole key intermediate and its derivative | 湖南大学 | 2017-09-22 | — | — | CN | claimed |
| US-5302390-A | ADMINISTERING TO TREAT THROMBOTIC DISEASES | BEECHAM GROUP PLC (GB) | 1994-04-12 | — | — | US | claimed |
| EP-0297882-B1 | HYBRID PLASMINOGEN ACTIVATORS | BEECHAM GROUP PLC (GB) | 1993-08-25 | — | — | EP | claimed |
| EP-0297882-A2 | Hybrid plasminogen activators | BEECHAM GROUP PLC (GB) | 1989-01-04 | — | — | EP | claimed |
| EP-4635568-A2 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA Pharmaceuticals Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4622967-A1 | COMPOUNDS THAT INHIBIT PKMYT1 | Exelixis, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| EP-4598535-A2 | INHIBITORS OF SPNS2 AND USES THEREOF | New York University (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-3672954-B1 | COMPOUNDS, SALTS THEREOF AND THEIR USE FOR THE TREATMENT OF DISEASES | ACADIA PHARM INC (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250197385-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARM INC (US) | 2025-06-19 | — | — | US | disclosed |
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-05-29 | — | — | US | disclosed |
| WO-2025085233-A1 | NOVEL DERIVATIVES OF QUINOLINONES, AND COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-5532374-A | Method of preparation of bis-quinolines | HITACHI CHEMICAL COMPANY, LTD. (JP) | 1996-07-02 | — | — | US | disclosed |
| US-5302390-A | ADMINISTERING TO TREAT THROMBOTIC DISEASES | BEECHAM GROUP PLC (GB) | 1994-04-12 | — | — | US | disclosed |
| EP-0297882-B1 | HYBRID PLASMINOGEN ACTIVATORS | BEECHAM GROUP PLC (GB) | 1993-08-25 | — | — | EP | disclosed |
| WO-1992004450-A1 | HYBRID PLASMINOGEN ACTIVATORS | BEECHAM GROUP PLC (GB) | 1992-03-19 | — | — | WO | disclosed |
| WO-1991018989-A1 | HYBRID PLASMINOGEN ACTIVATOR MUTANTS | BEECHAM GROUP PLC (GB) | 1991-12-12 | — | — | WO | disclosed |
| EP-0370711-A1 | Novel compounds | BEECHAM GROUP PLC (GB) | 1990-05-30 | — | — | EP | disclosed |
| EP-0297882-A2 | Hybrid plasminogen activators | BEECHAM GROUP PLC (GB) | 1989-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197385-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, CYP27A1, CYP11B2 | ALDH1A1 240/4885KDM4E 4595/4885BACE1 1161/4885 |
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | IGF1R, TRHR, TSHR | ALDH1A1 1694/4885KDM4E 2811/4885BACE1 3032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.